Nj State Employees Deferred Compensation Plan Verve Therapeutics, Inc. Transaction History
Nj State Employees Deferred Compensation Plan
- $800 Million
- Q4 2024
A detailed history of Nj State Employees Deferred Compensation Plan transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Nj State Employees Deferred Compensation Plan holds 14,000 shares of VERV stock, worth $101,920. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,000
Previous 14,000
-0.0%
Holding current value
$101,920
Previous $67,000
16.42%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding VERV
# of Institutions
180Shares Held
76.4MCall Options Held
70.3KPut Options Held
194K-
Alphabet Inc. Mountain View, CA12.3MShares$89.9 Million4.92% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$50.3 Million1.46% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$48.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$29.2 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$29.1 Million1.94% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $436M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...